SkylineDx Opens US Office to Market Multiple Myeloma Test to American Clinicians, Pharma | GenomeWeb

Dutch molecular diagnostics company SkylineDx recently established a presence in Boston to bolster its outreach to the North American market.

The Rotterdam-based firm, which has developed and launched microarray-based tests for acute myeloid leukemia and multiple myeloma in the EU, is now setting its sights on US clinicians and customers, according to Chris Williams, SkylineDx's vice president of business development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.